Century Therapeutics, Inc.

NasdaqGS:IPSC Voorraadrapport

Marktkapitalisatie: US$106.7m

Century Therapeutics Beheer

Beheer criteriumcontroles 1/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Brent Pfeiffenberger

Algemeen directeur

US$3.2m

Totale compensatie

Percentage CEO-salaris1.5%
Dienstverband CEOless than a year
Eigendom CEOn/a
Management gemiddelde ambtstermijnless than a year
Gemiddelde ambtstermijn bestuur3.5yrs

Recente managementupdates

Recent updates

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Jun 20

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Mar 06
Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Feb 01

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Oct 23
We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Aug 25

Analyse CEO-vergoeding

Hoe is Brent Pfeiffenberger's beloning veranderd ten opzichte van Century Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$131m

Mar 31 2024n/an/a

-US$133m

Dec 31 2023US$3mUS$50k

-US$137m

Compensatie versus markt: Brent's total compensation ($USD3.24M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Insufficient data to compare Brent's compensation with company performance.

CEO

Brent Pfeiffenberger

less than a year

Tenure

US$3,235,011

Compensatie

Mr. Brent Pfeiffenberger, Pharm D., MBA, has been Chief Executive Officer and Director of Century Therapeutics, Inc. since December 04, 2023. He served as Chief Operating Officer at Neogene Therapeutics, I...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Brent Pfeiffenberger
CEO & Directorless than a yearUS$3.24mgeen gegevens
Adrienne Farid
COO & Head of Early Development3.6yrsUS$1.71m0.10%
$ 106.9k
Gregory Russotti
Chief Technology & Manufacturing Officerless than a yearUS$2.59m0.41%
$ 433.1k
Morgan Conn
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Chad Cowan
Chief Scientific Officerless than a yeargeen gegevens0.17%
$ 185.4k
Kenneth Dow
Senior VP of General Counselno datageen gegevensgeen gegevens
Shane Williams
Chief People Officerno datageen gegevensgeen gegevens
Michael Naso
Senior VP of Cell Engineering1.5yrsgeen gegevensgeen gegevens
Nick Trede
Senior VP & Head of Clinical Development1.8yrsgeen gegevensgeen gegevens
Katja Buhrer
SVP, Head of Corporate Affairs & Strategyno datageen gegevensgeen gegevens
Douglas Carr
Senior VP of Finance & Operations and Secretaryno datageen gegevens0.28%
$ 293.9k

0.9yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: IPSC's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Brent Pfeiffenberger
CEO & Directorless than a yearUS$3.24mgeen gegevens
Cynthia Butitta
Independent Director3.8yrsUS$170.65k0.12%
$ 124.7k
Joseph Jimenez
Independent Chairman of the Board5.8yrsUS$197.40k0.58%
$ 622.9k
Timothy Walbert
Independent Director2.2yrsUS$159.40k0%
$ 0
Alessandro Riva
Independent Director3.5yrsUS$161.90k0%
$ 0
Daphne Quimi
Independent Director2.2yrsUS$169.65k0.0059%
$ 6.3k
Carlo Rizzuto
Independent Director3.8yrsUS$168.40k0%
$ 0
Kimberly Blackwell
Independent Director3.5yrsUS$165.90k0%
$ 0

3.5yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: IPSC's board of directors are considered experienced (3.5 years average tenure).